Retatrutide vs Semaglutide: A Drug Still in Trials vs One You Can Start Now

On trial numbers alone, retatrutide vs semaglutide is not close. In TRIUMPH-1, the first phase 3 obesity trial of retatrutide to reach a peer-reviewed journal, adults on the 12 mg dose lost an average of 25.0% of their body weight over 80 weeks (NEJM, 2026). In STEP 1, adults on semaglutide 2.4 mg lost 14.9% over 68 weeks.

Access runs the other way. Retatrutide is not FDA-approved for any use, federal law bars pharmacies from compounding it, and no application for approval had been filed as of October 2026. Semaglutide is approved as Wegovy for weight management and as Ozempic and Rybelsus for type 2 diabetes, and a licensed clinician can prescribe it today.

The trade, then: a larger trial number with no approval date, or an approved medication you can start now.

Both drugs copy hormones the gut releases after a meal: they slow how fast the stomach empties, turn down appetite signals in the brain and help the pancreas release insulin when blood sugar rises. The difference is how many receptors each one targets.

Semaglutide: one receptor

Semaglutide works through the GLP-1 receptor alone, and that one receptor carries the appetite effect many patients describe as food noise going quiet. It comes as a weekly injection (Wegovy, Ozempic) and as a daily tablet (Wegovy tablets for weight, Rybelsus for diabetes). Our guide to how semaglutide works for weight loss covers the mechanism in depth.

Retatrutide: three receptors

Retatrutide activates three: GIP, GLP-1 and glucagon. GIP is the second receptor tirzepatide uses. Glucagon is what sets retatrutide apart from both semaglutide and tirzepatide, and it is also the receptor with the shortest track record in people. In trials it is a once-weekly injection studied at 4, 9 and 12 mg.

If you are weighing all three, our tirzepatide vs retatrutide comparison covers the middle option.

No completed trial has compared the two drugs for weight loss. Read the gap as a direction, not a measurement.

Semaglutide on the label

In STEP 1, adults without diabetes on 2.4 mg a week lost an average of 14.9% of body weight at 68 weeks, against 2.4% on placebo. The daily 25 mg Wegovy tablet produced 13.6% at 64 weeks, and the 7.2 mg weekly dose approved in March 2026 produced 18.8% at 72 weeks against 3.9% (Wegovy prescribing information).

Then there is SELECT, in which 17,604 adults with heart disease and overweight or obesity had a 20% lower risk of cardiovascular death, heart attack or stroke on semaglutide than on placebo. Our article on what the SELECT trial means for you explains who that applies to.

Retatrutide in phase 3

TRIUMPH-1 randomized 2,339 adults with obesity and no diabetes. At 80 weeks, mean weight change was 17.6% on 4 mg, 23.7% on 9 mg and 25.0% on 12 mg, against 3.9% on placebo. TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, reported 11.9%, 16.8% and 18.8% against 5.1% (The Lancet, 2026). Headlines often quote bigger numbers, and those come from the manufacturer's analysis of people who stayed on treatment, which runs higher than the published figures.

The one head-to-head trial

TRANSCEND-T2D-2 compares the two drugs in about 1,250 adults with type 2 diabetes already taking metformin, and its main measure is HbA1c at 80 weeks, not weight. Primary data collection ended in August 2026. No results have been reported (ClinicalTrials.gov).

Scroll the table sideways to see both columns →

The side-effect profiles look more alike than the weight-loss numbers do.

What they share

Both are mainly gastrointestinal, both depend on dose, and both are worst in the weeks after a dose increase. On Wegovy 2.4 mg, 44% of adults reported nausea and 30% diarrhea, against 16% each on placebo, and 6.8% stopped treatment because of side effects. In TRIUMPH-2, diarrhea affected 27% to 34% of people on retatrutide and nausea 14% to 28%, against 13% and 8% on placebo.

Where the signals differ

Dysesthesia, an abnormal skin sensation such as tingling or tenderness, was reported by 4% to 7% of people on retatrutide in TRIUMPH-2, against 1% on placebo, and up to 6% had low blood pressure. The phase 2 trial also found a dose-dependent rise in resting heart rate that peaked around week 24 and eased afterward.

Neither signal is retatrutide's alone. The Wegovy label lists dysesthesia in 22% of adults on the 7.2 mg dose, and heart-rate increases averaging 1 to 4 beats per minute across semaglutide's weight trials. Semaglutide's effects are printed on a label. Retatrutide's are still being mapped.

A boxed warning sits on semaglutide for thyroid C-cell tumors seen in rodents, and it is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

Retatrutide is not on FDA's list of new drugs approved in 2026 (FDA). The manufacturer said in its August 2026 earnings filing that it plans to submit an application in the first quarter of 2027. Approval would follow FDA's review, and no date has been set.

FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition (FDA). Vials sold online as retatrutide, often labeled "research peptide" or "not for human consumption," are unapproved products of unknown quality, and FDA has sent warning letters to the companies selling them.

If retatrutide caught your eye because semaglutide did not do enough for you, there is an approved drug that hits two of its three receptors. Tirzepatide, the GIP and GLP-1 drug sold as Zepbound and Mounjaro, produced 20.2% average weight loss against 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial (NEJM, 2025).

Until FDA approves retatrutide, no clinician can write a regular prescription for it, Harbor's included. So the real choice today is between approved molecules, and the first plan is rarely the last.

Start semaglutide now when

• You want to begin now rather than wait on a drug with no approval date
• Cost matters, since semaglutide is the lower-priced of Harbor's two GLP-1 programs
• You have heart disease, where the SELECT evidence sits behind semaglutide
• This is your first GLP-1 and a gentler start matters more than the largest average result

Ask about tirzepatide when

• You have tried semaglutide and progress stalled short of your goal
• Your starting weight is high enough that a larger average effect changes what is realistic
• You were drawn to retatrutide for its GIP action and want the approved molecule that has it

Starting semaglutide now closes no door. If retatrutide is approved, moving to it would be a clinical decision like any other switch between GLP-1 medications, based on your dose, response and history.